Trials / Completed
CompletedNCT05872620
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,613 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Orforglipron | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2023-06-05
- Primary completion
- 2025-08-08
- Completion
- 2025-08-08
- First posted
- 2023-05-24
- Last updated
- 2025-09-18
Locations
136 sites across 11 countries: United States, Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, Puerto Rico, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05872620. Inclusion in this directory is not an endorsement.